MX2017004760A - Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma. - Google Patents

Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.

Info

Publication number
MX2017004760A
MX2017004760A MX2017004760A MX2017004760A MX2017004760A MX 2017004760 A MX2017004760 A MX 2017004760A MX 2017004760 A MX2017004760 A MX 2017004760A MX 2017004760 A MX2017004760 A MX 2017004760A MX 2017004760 A MX2017004760 A MX 2017004760A
Authority
MX
Mexico
Prior art keywords
preparation
heat
chitosan
sterilized formulation
relates
Prior art date
Application number
MX2017004760A
Other languages
English (en)
Inventor
Yolanda Bossy Leila
Di Napoli Alessandro
Original Assignee
Laboratoire Medidom Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Medidom Sa filed Critical Laboratoire Medidom Sa
Publication of MX2017004760A publication Critical patent/MX2017004760A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/05—Alcohols; Metal alcoholates
    • C08K5/053—Polyhydroxylic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/719—Pullulans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L3/00—Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08L3/12—Amylose; Amylopectin; Degradation products thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2201/00—Properties
    • C08L2201/10—Transparent films; Clear coatings; Transparent materials
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2201/00—Properties
    • C08L2201/54—Aqueous solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición acuosa esterilizada al calor que comprende un quitosán solubilizado y glicerol. También se refiere a un proceso de preparación de la misma, así como el uso del mismo, incluyendo composiciones útiles para la prevención y el tratamiento del síndrome del ojo seco y enfermedades artríticas o trastornos.
MX2017004760A 2014-10-29 2015-10-28 Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma. MX2017004760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2014/073246 WO2016066195A1 (en) 2014-10-29 2014-10-29 Heat-sterilized formulation comprising chitosan and process of preparation thereof
PCT/IB2015/058300 WO2016067210A1 (en) 2014-10-29 2015-10-28 Heat-sterilized formulation comprising chitosan and process of preparation thereof

Publications (1)

Publication Number Publication Date
MX2017004760A true MX2017004760A (es) 2017-07-26

Family

ID=51842529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004760A MX2017004760A (es) 2014-10-29 2015-10-28 Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.

Country Status (17)

Country Link
US (1) US10493155B2 (es)
EP (1) EP3212166B1 (es)
JP (1) JP6814133B2 (es)
KR (1) KR102421423B1 (es)
CN (1) CN107075174B (es)
CA (1) CA2965447C (es)
CO (1) CO2017003840A2 (es)
DK (1) DK3212166T3 (es)
ES (1) ES2857273T3 (es)
HR (1) HRP20201995T1 (es)
HU (1) HUE053432T2 (es)
MX (1) MX2017004760A (es)
PT (1) PT3212166T (es)
RS (1) RS61214B1 (es)
RU (1) RU2712271C2 (es)
SI (1) SI3212166T1 (es)
WO (2) WO2016066195A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310665A (zh) 2016-04-14 2019-02-05 阿祖拉眼科有限公司 用于治疗睑板腺功能障碍的二硫化硒组合物
US10576099B2 (en) 2016-10-21 2020-03-03 Covidien Lp Injectable scaffold for treatment of intracranial aneurysms and related technology
US11452783B2 (en) * 2017-02-14 2022-09-27 Gi Supply Tissue stain and use thereof
JP2022529314A (ja) * 2019-04-12 2022-06-21 アズーラ オフサルミックス エルティーディー． コンタクトレンズ不快感を処置するための組成物および方法
JP7453036B2 (ja) 2020-03-30 2024-03-19 株式会社ナリス化粧品 皮膚外用剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659700A (en) * 1984-03-02 1987-04-21 Johnson & Johnson Products, Inc. Chitosan-glycerol-water gel
JPS6462302A (en) * 1987-09-01 1989-03-08 Nippon Suisan Kaisha Ltd Water-soluble chitosan salt and production thereof
JPH06107551A (ja) * 1992-09-30 1994-04-19 Hisamitsu Pharmaceut Co Inc 関節症治療剤
JPH07118304A (ja) * 1993-10-27 1995-05-09 Asahi Glass Co Ltd キトサン水溶液
US5420197A (en) * 1994-01-13 1995-05-30 Hydromer, Inc. Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives
WO1997007139A2 (en) 1995-08-17 1997-02-27 Novartis Ag Stabilized chitin derivative compounds
SI1128809T1 (en) * 1998-11-20 2005-06-30 Laboratoire Medidom S.A. Aqueous ophthalmic formulations comprising chitosan
JP5116129B2 (ja) * 2000-09-01 2013-01-09 日本水産株式会社 中性付近のキトサン水溶液の製造法
US20020119949A1 (en) * 2001-02-26 2002-08-29 Asa Hellman Prophylactic teat treatment
CA2501820C (en) * 2002-10-08 2009-12-15 Ricom Corporation Chitosan-containing polysaccharide, method for preparing the same and use thereof
BRPI0520742A2 (pt) * 2005-12-23 2010-01-12 Medidom Lab composição de quitosana neutralizada termoestável que forma um hidrogel, produto liofilizado, e processos para produzir a mesma
US9034348B2 (en) * 2006-12-11 2015-05-19 Chi2Gel Ltd. Injectable chitosan mixtures forming hydrogels
US20090142292A1 (en) * 2007-12-03 2009-06-04 Blackwell Richard I Method For The Mitigation of Symptoms of Dry Eye

Also Published As

Publication number Publication date
ES2857273T3 (es) 2021-09-28
CN107075174A (zh) 2017-08-18
EP3212166B1 (en) 2020-12-02
RU2017118261A (ru) 2018-11-29
CN107075174B (zh) 2021-03-30
US10493155B2 (en) 2019-12-03
HRP20201995T1 (hr) 2021-02-05
JP6814133B2 (ja) 2021-01-13
SI3212166T1 (sl) 2021-01-29
US20170312364A1 (en) 2017-11-02
RU2017118261A3 (es) 2019-04-25
PT3212166T (pt) 2021-02-09
JP2017533186A (ja) 2017-11-09
CA2965447A1 (en) 2016-05-06
CA2965447C (en) 2022-05-31
RU2712271C2 (ru) 2020-01-28
DK3212166T3 (da) 2021-02-22
WO2016067210A1 (en) 2016-05-06
BR112017008353A2 (pt) 2017-12-19
KR20170076659A (ko) 2017-07-04
EP3212166A1 (en) 2017-09-06
WO2016066195A1 (en) 2016-05-06
RS61214B1 (sr) 2021-01-29
HUE053432T2 (hu) 2021-07-28
KR102421423B1 (ko) 2022-07-15
CO2017003840A2 (es) 2017-04-28

Similar Documents

Publication Publication Date Title
PH12018500057A1 (en) Substituted oxopyridine derivatives
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
TW201613901A (en) New compounds
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12016501807A1 (en) Novel compounds
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2016010328A (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
IN2013MU03583A (es)
PH12017501133A1 (en) Pyrazolopyridinamines
TN2016000435A1 (en) Novel macrocyclic compounds.
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
WO2016100615A3 (en) Methods and composition for neutralization of influenza
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
WO2015001541A3 (en) Pharmaceutical film composition
EP3199163A4 (en) Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies